Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Cidofovir (CDV) is an effective drug against viruses of the Orthopoxviridae family and is active in vitro against variola virus, the cause of smallpox. However, CDV-resistant poxviruses can be generated by repeated in vitro passage in the presence of suboptimal concentrations of CDV. To determine if mutations in the E9L polymerase gene could confer resistance to this nucleoside analog, this gene was sequenced from CDV-resistant vaccinia virus and found to encode five amino acid changes, centered on an N-terminal region associated with 3'-->5' exonuclease activity. Transfer of this mutant E9L gene into wild-type vaccinia virus by marker rescue sufficed to confer the resistance phenotype. E9L polymerase mutations occurred sequentially during passage in CDV, and an H296Y/S338F double mutant that conferred an intermediate CDV resistance phenotype was identified. In vitro, the marker-rescued CDV-resistant vaccinia virus containing all five mutations grew nearly as well as wild-type vaccinia virus. However, the virulence of this virus for mice was reduced, as 10- to 30-fold more CDV-resistant virus than wild-type virus was required for lethality following intranasal challenge. Cidofovir and hexadecyloxypropyl-cidofovir gave partial protection to mice infected with the virus when used at 50 and 100 mg/kg of body weight given as single treatments 24 h after virus exposure, whereas 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (compound S2242) was completely protective at 25, 50, and 100 mg/kg/day when given daily for 5 days. These findings suggest that drug therapy for poxviruses may be complicated by drug resistance but that treatment of the infection with currently known compounds is possible.
Kornbluth
Richard S
RS
Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0676, USA.
Smee
Donald F
DF
Sidwell
Robert W
RW
Snarsky
Victoria
V
Evans
David H
DH
Hostetler
Karl Y
KY
D000281:Administration, Intranasal; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002522:Chlorocebus aethiops; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004259:DNA-Directed DNA Polymerase / Q000235:genetics*; D004195:Disease Models, Animal; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005814:Genes, Viral; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D063065:Organophosphonates / Q000008:administration & dosage / Q000494:pharmacology*; D010641:Phenotype; D013047:Specific Pathogen-Free Organisms; D014615:Vaccinia / Q000821:virology*; D014616:Vaccinia virus / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D014709:Vero Cells
D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D004259:DNA-Directed DNA Polymerase; D000077404:Cidofovir